J 2018

Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study

VINDIS, David; Martin HUTYRA; Daniel SANAK; Michal KRAL; Eva CECHAKOVA et. al.

Základní údaje

Originální název

Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study

Autoři

VINDIS, David (203 Česká republika); Martin HUTYRA (203 Česká republika, garant); Daniel SANAK (203 Česká republika); Michal KRAL (203 Česká republika); Eva CECHAKOVA (203 Česká republika); Simona LITTNEROVÁ (203 Česká republika, domácí); Tomas ADAM (203 Česká republika); Jan PRECEK (203 Česká republika); Stepan HUDEC (203 Česká republika); Marketa JECMENOVA (203 Česká republika) a Milos TABORSKY (203 Česká republika)

Vydání

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, AMSTERDAM, ELSEVIER SCIENCE BV, 2018, 1052-3057

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30103 Neurosciences

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.646

Kód RIV

RIV/00216224:14110/18:00104069

Organizační jednotka

Lékařská fakulta

UT WoS

000419585800019

EID Scopus

2-s2.0-85030864185

Klíčová slova anglicky

Pulmonary embolism; patent foramen ovale; brain infarction; echocardiography; brain magnetic resonance imaging

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 10. 2. 2019 17:15, Soňa Böhmová

Anotace

V originále

Background: Pulmonary embolism (PE) is associated with a risk of consecutive paradoxical embolism with brain infarction through a patent foramen ovale (PFO). The aims of this study were to assess the rate of new ischemic brain lesions (IBLs) using magnetic resonance imaging (MRI) during a 12-month follow-up period with anticoagulation and to evaluate the potential relationship with the presence of PFO on transesophageal echocardiography (TEE). Subjects and Methods: Seventy-eight patients with acute PE underwent baseline contrast TEE with brain MRI. After the 12-month follow-up, 58 underwent brain MRI. The rates of MRI documenting new IBLs were measured based on the presence of PFO. Results: PFO was detected in 31 patients (39.7%). At baseline MRI, IBL was present in 39 of 78 patients (50%). The presence of IBL was not significantly higher in patients with PFO than in patients without PFO (20 [64.5% patients with PFO] versus 19 [40.4% without PFO] of 39 patients with baseline IBL, P = .063). At the follow-up MRI, in the group with new IBL (9 of 58 patients, 15.5%), the number of patients with PFO was significantly higher than that without PFO (7 [33.3%] versus 2 [5.4%], P = .008). PFO was identified as an independent predictor of new IBL (odds ratio 4.6 [1.6-47.4], P = .008). Conclusions: The presence of PFO was associated with new IBL in patients with PE. These patients are at a higher risk of ischemic stroke despite effective anticoagulation therapy.